Qantas Airways: The market still doesn’t believe this isn’t the top
About the author:
- Author name:
- By Billy Boulton
- Job title:
- Associate Analyst
- Date posted:
- 25 August 2023, 10:00 AM
- Sectors Covered:
- Agriculture, Travel, Chemicals, Food & Beverage
- Qantas Airways' (ASX:QAN) FY23 result was a record and all in line with recent guidance provided at its May trading update. The company continues to show confidence in its outlook and balance sheet (despite record upcoming capex spend) with it announcing another A$500m on-market share buyback (above MorgansF of A$400m).
- Whilst we were hoping for a stronger message from QAN around earnings growth being delivered in FY24, outlook commentary was upbeat nonetheless. QAN reiterated its FY24 EBIT margin targets and also said that travel demand remains very strong and that it is seeing solid trading into the 1H24.
- From here, 1H24 guidance likely provided in Oct/Nov will be the key share price catalyst. With QAN trading on its lowest P/E multiple in years (FY24F of 5.4x post buybacks), risk remains materially skewed to the upside. ADD maintained.
Find out more
Download full research note
You can find further detailed analysis of company results this reporting season by browsing our reporting season tag, and view a full list of upcoming results on our Reporting Season Calendar.
If you would like more information, please contact your adviser or nearest Morgans office.
Request a call
Find local branch
Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.
Print this page